Efficacy and Safety of Nexpowder™ for Non-variceal, Upper Gastrointestinal Bleeding
Launched by CHANGI GENERAL HOSPITAL · Feb 13, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a new treatment called Nexpowder™ to see how well it works and how safe it is for patients who have non-variceal upper gastrointestinal bleeding, which is bleeding in the upper part of the digestive system. The trial is currently looking for participants in Singapore, and people between the ages of 21 and 75 who have this type of bleeding may be eligible to join. To participate, individuals must agree to take part in the study and follow the guidelines provided.
If you decide to join this trial, you will receive treatment with Nexpowder™ and will be monitored to assess how well it stops the bleeding and if there are any side effects. It’s important to note that some people may not qualify, such as those with certain blood disorders or those who are pregnant. This trial aims to gather important information that could help improve treatments for patients experiencing similar bleeding issues in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Males or females aged over 21 to 75 years
- • 2. Patients with confirmed nonvariceal, upper gastrointestinal bleeding
- • 3. Patients who voluntarily agree to the clinical trial with informed consent
- • 4. Patients who willing and able to comply with the study protocol
- Exclusion Criteria:
- • 1. Patients with an uncorrected coagulation disorder (PLT\<50\*109/L, INR\>2)
- • 2. Patients who are known to be pregnant or in lactation
- • 3. Patients who have received another endoscopic treatment for the same part of the body within the days preceding the study
- • 4. Patients for whom endoscopic treatment is prohibited due to comorbidity
- • 5. Patients for whom the 30-day follow-up period is impossible
- • 6. Patients who have participated within the past month in other related clinical trials that could affect the results of the study
- • 7. Other cases in which participation in the study is judged inappropriate by the investigators
About Changi General Hospital
Changi General Hospital (CGH) is a leading tertiary healthcare institution in Singapore, renowned for its commitment to providing high-quality patient care and advancing medical research. As a sponsor of clinical trials, CGH leverages its state-of-the-art facilities and multidisciplinary expertise to facilitate innovative research that aims to enhance treatment options and improve patient outcomes. The hospital is dedicated to upholding rigorous ethical standards and regulatory compliance while fostering collaboration with healthcare professionals and researchers to drive advancements in medical science. Through its clinical trials, CGH seeks to contribute to the global body of knowledge and translate research findings into practical applications for better healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Singapore, , Singapore
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported